Soltis Investment Advisors LLC Has $3.22 Million Stake in Kenvue Inc. (NYSE:KVUE)

Soltis Investment Advisors LLC reduced its position in shares of Kenvue Inc. (NYSE:KVUE) by 0.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 150,709 shares of the company’s stock after selling 1,149 shares during the quarter. Soltis Investment Advisors LLC’s holdings in Kenvue were worth $3,218,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. Grove Bank & Trust grew its holdings in shares of Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after buying an additional 947 shares in the last quarter. Riverview Trust Co purchased a new position in Kenvue during the 3rd quarter valued at about $30,000. Geneos Wealth Management Inc. acquired a new position in shares of Kenvue in the 4th quarter valued at about $29,000. Ashton Thomas Securities LLC purchased a new stake in shares of Kenvue in the third quarter worth approximately $35,000. Finally, Fortitude Family Office LLC lifted its position in shares of Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after purchasing an additional 777 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Trading Up 2.2 %

Shares of KVUE stock opened at $20.23 on Monday. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a market cap of $38.79 billion, a PE ratio of 38.17, a price-to-earnings-growth ratio of 2.16 and a beta of 1.45. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The business’s 50 day moving average is $21.54 and its two-hundred day moving average is $21.97.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities analysts predict that Kenvue Inc. will post 1.05 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be paid a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 4.05%. Kenvue’s payout ratio is 154.72%.

Wall Street Analyst Weigh In

Several research firms have weighed in on KVUE. Citigroup dropped their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Canaccord Genuity Group dropped their price target on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a research note on Friday. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and cut their price objective for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. UBS Group lowered their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday. Finally, Barclays cut their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research note on Friday, January 17th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $23.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.